A Dose Response Study of Levalbuterol and Racemic Albuterol HFA MDI in Pediatric Subjects With Asthma
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 33
- 主要终点
- Maximum percent decrease in FEV1 from visit post-dose/pre-challenge FEV1
研究概览
简要总结
The purpose of this study is to investigate, using an exercise challenge approach, the dose response of levalbuterol HFA MDI in pediatric subjects with asthma
详细描述
A randomized, double-blind, active controlled, multicenter, parallel treatment, 3x3 dose level crossover study evaluating the dose response of levalbuterol in pediatric subjects between the ages of 6 and 11, inclusive with exercise induced bronchoconstriction. This study was previously posted by Sepracor Inc. In October 2009, Sepracor Inc. was acquired by Dainippon Sumitomo Pharma., and in October 2010, Sepracor Inc's name was changed to Sunovion Pharmaceuticals Inc.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 6 Years 至 11 Years（Child）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Subject, male or female, must be between the ages of 6 to 11 years, inclusive, at the time of consent.
- •Female subjects who are 8 years of age or older must have a negative serum pregnancy test.
- •Subject must have a documented diagnosis of asthma for a minimum of 6 months prior to study start
- •Subject must be in good health with the exception of their reversible airways disease and not suffering from any chronic condition that might affect their respiratory function.
- •Subject must have a chest X-ray for the study or within 12 months prior to randomization.
- •Subject's parent/legal guardian must be able to complete the diary cards and medical event calendars reliably on a daily basis and understand dosing instructions. Any minor subject who is not able to do this must have a parent/legal guardian who can assist them during the study with these activities.
排除标准
- •Female subject who is pregnant or lactating.
- •Subject who has participated in an investigational drug study within 30 days of study start, or who is currently participating in another clinical trial.
- •Subject whose schedule prevents him or her from starting study visits before 2:30-4:00 PM.
- •Subject who is unwilling or physically unable to perform the exercise challenges as described in the protocol.
- •Subject who has travel commitments during the study that would interfere with trial measurements or compliance or both.
- •Subject who has a history of hospitalization for asthma within 4 weeks prior to study start, or who is scheduled for in-patient hospitalization, including elective surgery during the course of the trial.
- •Subject with a known sensitivity to levalbuterol or racemic albuterol, or any of the excipients contained in any of these formulations.
- •Subject using any prescription drug with which albuterol sulfate administration is contraindicated.
- •Subject with currently diagnosed life-threatening asthma defined as a history of asthma episodes requiring intubation, associated with hypercapnia, respiratory arrest, or hypoxic seizures within 3 months prior to study start.
- •Subject with a history of cancer (exception: basal cell carcinoma in remission).
- •Subject with hyperthyroidism, diabetes, hypertension, cardiac diseases or seizure disorders.
- •Subject with a history of substance abuse or drug abuse within 12 months preceding study start.
- •Subject with a history of cigarette smoking or use of any tobacco products.
- •Subject with a documented history of bronchopulmonary aspergillosis or any form of allergic alveolitis.
- •Subject who has suffered from a clinically significant upper or lower respiratory tract infection in the 3 weeks prior to study start.
- •Subjects with unstable asthma; or who have had a change in asthma therapy; or a visit to the Emergency Department or hospital for worsening asthma within 4 weeks.
- •Subject who is a staff member or relative of a staff member.
研究组 & 干预措施
A
Subjects randomized to the levalbuterol arm will complete 1 of 6 possible randomization sequences containing (a) levalbuterol 45 µg (1 actuation of 45 µg); (b) levalbuterol 90 µg (2 actuation of 45 µg) and (c) levalbuterol 180 µg (4 actuations of 45 µg each). Subjects will receive treatment, according to the randomization sequence, followed by a 5±2 day washout.
干预措施: Levalbuterol HFA MDI (Drug)
B
Subjects randomized to racemic albuterol will complete 1 of 6 possible randomization sequences containing (a) racemic albuterol 90 µg (1 actuation of 90 µg); (b) racemic albuterol 180 µg (2 actuations of 90 µg) and (c) racemic albuterol 360 µg (4 actuations of 90 µg). Subjects will receive treatment, according to the randomization sequence, followed by a 5±2 day washout.
干预措施: Racemic Albuterol (Drug)
结局指标
主要结局
Maximum percent decrease in FEV1 from visit post-dose/pre-challenge FEV1
时间窗: Days -7, 0, 5, 10, 15
次要结局
- Area under the percent decrease from visit post-dose/pre-challenge FEV1 curve(Days -7, 0, 5, 10, 15)
- Area under the percent decrease from visit pre-dose FEV1 curve.(Days -7, 0, 5, 10, 15)
- Minimum percent change in FEV1 from visit pre-dose FEV1.(Days -7, 0, 5, 10, 15)
- Minimum percent change in FEV1 from visit post dose/pre-challenge FEV1(Days -7, 0, 5, 10, 15)
- percent change in FEV1 from visit predose to the post-dose/pre-challenge FEV1(Days -7, 0, 5, 10, 15)
- Time to recovery (min), Protected/Unprotected Subjects Counts(Days -7, 0, 5, 10, 15)
- Area under the percent decrease from visit post-dose/pre-challenge FVC,(Days -7, 0, 5, 10, 15)
- Maximum percent decrease in FVC from visit post-dose/pre-challenge FVC(Days -7, 0, 5, 10, 15)
- Minimum percent change in FVC from pre-dose FVC(Days -7, 0, 5, 10, 15)
- Area under the percent decrease from visit post-dose/pre-challenge FEF25%-75% curve(Days -7, 0, 5, 10, 15)
- Maximum percent decrease in FEF25-75% from visit post-dose/pre-challenge FEF25-75%(Days -7, 0, 5, 10, 15)
- Minimum percent change in FEF25%-75% from visit pre-dose FEF25-75%.(Days -7, 0, 5, 10, 15)